Sunshine Guojian Pharmaceutical(Shanghai)Co.,Ltd.(688336),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

688336 Sunshine Guojian Pharmaceutical(Shanghai)Co.,Ltd.

Closed 04-03 15:00:00

92.30

+1.92

+2.12%

High96.60	Low88.00	Vol19.25M
Open88.80	D1 Closing90.38	Amplitude9.52%
Mkt Cap57.04B	Tradable Cap56.95B	Total Shares618.00M
T/O1.77B	T/O Rate3.12%	Tradable Shares617.00M
P/B6.75	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"688336","market":"SH","secType":"STK","nameCN":"Sunshine Guojian Pharmaceutical(Shanghai)Co.,Ltd.","latestPrice":92.3,"timestamp":1775199600000,"preClose":90.38,"halted":0,"volume":19247546,"delay":0,"changeRate":0.0212,"floatShares":617000000,"shares":618000000,"eps":8.2417,"marketStatus":"Closed","change":1.92,"latestTime":"04-03 15:00:00","open":88.8,"high":96.6,"low":88,"amount":1771000000,"amplitude":0.0952,"askPrice":92.31,"askSize":2,"bidPrice":92.3,"bidSize":482,"shortable":0,"etf":0,"ttmEps":8.2417,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1775525400000},"marketStatusCode":5,"adr":0,"adjPreClose":90.38,"symbolType":"stock_kcb","openAndCloseTimeList":[[1775179800000,1775187000000],[1775192400000,1775199600000]],"highLimit":99.42,"lowLimit":81.34,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":618086503,"isCdr":false,"pbRate":6.75,"roa":"--","peRate":11.199146,"roe":"41.32%","epsLYR":4.7,"committee":0.482295,"marketValue":57049000000,"turnoverRate":0.0312,"status":0,"nextConnectDate":"Northbound have stopped. The next trading day is UTC+8 2026-04-08.","afterMarket":{"amount":46150,"volume":500,"close":92.3,"buyVolume":600,"sellVolume":0,"time":1775201637919,"indexStatus":"Closed 04-03 15:30:00","preClose":90.38},"floatMarketCap":56929000000},"requestUrl":"/m/hq/s/688336/wiki","defaultTab":"wiki","newsList":[{"id":"1157926346","title":"Pharmaceutical Sector Defies Market Downturn with Strong Resilience","url":"https://stock-news.laohu8.com/highlight/detail?id=1157926346","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157926346?lang=en_us&edition=fundamental","pubTime":"2026-04-02 14:41","pubTimestamp":1775112077,"startTime":"0","endTime":"0","summary":"On the afternoon of April 2, A-shares accelerated their decline, with the Shanghai Composite Index falling over 1%. The pharmaceutical sector bucked the trend, demonstrating notable resilience. The...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["562050","BK1191","01477","BK1574","688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624518885","title":"Sunshine Guojian Pharmaceutical's Attributable Profit Soars 311%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624518885","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624518885?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:32","pubTimestamp":1775043168,"startTime":"0","endTime":"0","summary":"Sunshine Guojian Pharmaceutical's  attributable profit soared 311% to 2.90 billion yuan in 2025 from 704.6 million yuan in 2024, according to a Tuesday filing with the Shanghai bourse.Earnings per share at the biotechnology products manufacturer surged to 4.68 yuan from 1.14 yuan in the previous year.Operating income grew 252% year over year to 4.20 billion yuan from 1.19 billion yuan.Shares closed 5% higher on Wednesday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614019098","title":"Chinese Drug Regulator Accepts Guojian Pharmaceutical's New Drug Application for Atopic Dermatitis Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2614019098","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614019098?lang=en_us&edition=fundamental","pubTime":"2026-02-26 12:43","pubTimestamp":1772081006,"startTime":"0","endTime":"0","summary":"China's National Medical Products Administration accepted Sunshine Guojian Pharmaceutical 's  new drug application for recombinant anti-IL-4Rα humanized monoclonal antibody injection or SSGJ-611, according to a Shanghai bourse filing on Thursday.The drug was developed to treat patients with atopic dermatitis.The pharmaceutical company's shares slipped less than 2% during the midday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170954211","title":"Sunshine Guojian's Novel IL-4Rα Antibody Therapy Advances with NDA Acceptance","url":"https://stock-news.laohu8.com/highlight/detail?id=1170954211","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170954211?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:28","pubTimestamp":1772026093,"startTime":"0","endTime":"0","summary":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (688336.SH) has announced the receipt of an acceptance notice from the National Medical Products Administration. The notice confirms that the New...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614706729","title":"Chinese Shares Rise on Tech Boost; Guojian Pharmaceutical Jumps 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614706729","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614706729?lang=en_us&edition=fundamental","pubTime":"2026-02-25 16:05","pubTimestamp":1772006714,"startTime":"0","endTime":"0","summary":"Chinese shares rose on Wednesday amid market optimism regarding technology companies' prospects in 2026.The Shanghai Composite Index, the main gauge of Chinese stocks, rose 0.7% to 4,147.23. The Shenzhen Component Index climbed 1.3% to 14,475.87.UBS said it expects China's technology industry to thrive this year due to higher investment and advancements in artificial intelligence, Investing.com reported.The brokerage said Chinese tech leaders invest far less than their American counterparts, but anticipates they will reveal larger spending budgets during upcoming financial reports. Unlike the US, where investors have started criticizing rapid spending increases, Chinese investors still support companies that boost their investments.UBS analysts foresee significant AI developments emerging from China in 2026, including stronger foundational models and innovative applications.In company news, Sunshine Guojian Pharmaceutical 's  attributable profit rose 317% to 2.94 billion yuan in 2025 f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"1629be81ac380d3588fb1b06271e9cce","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117737106","title":"Sunshine Guojian Reports 2025 Net Profit of 2.94 Billion Yuan, Surging 317%","url":"https://stock-news.laohu8.com/highlight/detail?id=1117737106","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117737106?lang=en_us&edition=fundamental","pubTime":"2026-02-24 16:24","pubTimestamp":1771921458,"startTime":"0","endTime":"0","summary":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (688336.SH) announced its 2025 financial results, revealing a significant increase in performance. The company's operating revenue for the year...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613932737","title":"BRIEF-Sunshine Guojian Pharmaceutical Shanghai's Prelim 2025 Net Profit Up 317.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613932737","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613932737?lang=en_us&edition=fundamental","pubTime":"2026-02-24 16:22","pubTimestamp":1771921341,"startTime":"0","endTime":"0","summary":"BRIEF-Sunshine Guojian Pharmaceutical Shanghai's Prelim 2025 Net Profit Up 317.1%Feb 24  - Sunshine Guojian Pharmaceutical Shanghai Co Ltd 688336.SS:PRELIM 2025 NET PROFIT UP 317.1%Source textFurther company coverage: 688336.SS  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nL4N3ZK0ON:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613793226","title":"Sunshine Guojian Pharmaceutical Shanghai  Prelim 2025 Net Profit up 317.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613793226","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613793226?lang=en_us&edition=fundamental","pubTime":"2026-02-24 16:22","pubTimestamp":1771921341,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nL4N3ZK0ON:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164647335","title":"Sunshine Guojian (688336.SH) Issues Positive Profit Alert, Forecasts 2025 Net Profit Attributable to Shareholders of Approx. 2.9 Billion Yuan, Up 311.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=1164647335","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164647335?lang=en_us&edition=fundamental","pubTime":"2026-01-26 19:54","pubTimestamp":1769428470,"startTime":"0","endTime":"0","summary":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (688336.SH) has released its annual performance forecast for 2025. The company anticipates achieving a net profit attributable to the owners of...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606572215","title":"BRIEF-Sunshine Guojian Pharmaceutical Shanghai Sees 2025 Net Profit Up About 311.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606572215","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606572215?lang=en_us&edition=fundamental","pubTime":"2026-01-26 17:27","pubTimestamp":1769419676,"startTime":"0","endTime":"0","summary":"BRIEF-Sunshine Guojian Pharmaceutical Shanghai Sees 2025 Net Profit Up About 311.4%Jan 26  - Sunshine Guojian Pharmaceutical Shanghai Co Ltd 688336.SS:SEES 2025 NET PROFIT UP ABOUT 311.4%Source textFurther company coverage: 688336.SS  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nL4N3YR0KM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182078276","title":"Decoding the Business Strategy of Hair Loss Drug Firm Mindy's IPO: Marketing Spend Six Times R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=1182078276","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182078276?lang=en_us&edition=fundamental","pubTime":"2025-11-26 01:46","pubTimestamp":1764092803,"startTime":"0","endTime":"0","summary":"A RMB 500 million investment made a decade ago by 3SBio (1580.HK) has now yielded nearly a tenfold return.   This investment originated from 3SBio’s acquisition of Mindy International (referred to as...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109456515","title":"Sunshine Guojian Challenges Mabgeek Biotech's Patent, Exposing Triple Risks in Its $2.6B IPO Bid","url":"https://stock-news.laohu8.com/highlight/detail?id=1109456515","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109456515?lang=en_us&edition=fundamental","pubTime":"2025-11-14 13:40","pubTimestamp":1763098855,"startTime":"0","endTime":"0","summary":"The patent battle between Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. and Mabgeek Biotech over IL-4R antibodies has intensified. On November 3, Sunshine Guojian publicly announced it had...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688336","BK0239","91209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108047705","title":"Sunshine Guojian Pharmaceutical (688336.SH): Dajia International Plans to Reduce Stake by Up to 1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1108047705","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108047705?lang=en_us&edition=fundamental","pubTime":"2025-11-09 15:40","pubTimestamp":1762674008,"startTime":"0","endTime":"0","summary":"Sunshine Guojian Pharmaceutical (688336.SH) announced that Dajia International intends to reduce its stake in the company by no more than 6.1679 million shares, or 1% of the total share capital,...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160027746","title":"Patent Battle Reignites Between Sunshine Guojian and Mabgeek Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=1160027746","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160027746?lang=en_us&edition=fundamental","pubTime":"2025-11-04 14:41","pubTimestamp":1762238469,"startTime":"0","endTime":"0","summary":"The patent war over core products has escalated again, casting uncertainty over Hunan Mabgeek Biotech's planned Hong Kong IPO. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. and Mabgeek...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","91209","688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134846156","title":"Sunshine Guojian Pharmaceutical (688336.SH): Pfizer Registers Two Global Phase III Trials for PD-1/VEGF Bispecific Antibody PF-08634404 (SSGJ-707), Final Payment Remains Uncertain","url":"https://stock-news.laohu8.com/highlight/detail?id=1134846156","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134846156?lang=en_us&edition=fundamental","pubTime":"2025-11-03 18:30","pubTimestamp":1762165830,"startTime":"0","endTime":"0","summary":"Sunshine Guojian Pharmaceutical (688336.SH) issued a stock price fluctuation announcement stating that the company, along with 3SBio and Shenyang Sunshine, has granted Pfizer (PFE) an exclusive...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4550","LU1894683348.USD","III","PD","LU0456855351.SGD","LU1066051498.USD","LU0306806265.USD","LU0985481810.HKD","BK4599","LU1883839398.USD","SGXZ57979304.SGD","SG9999002224.SGD","LU0234572021.USD","BK4134","LU1169590202.USD","BK4534","BK4007","LU0868494617.USD","BK4023","BK4533","BK4592","IE00BLSP4452.SGD","LU1023059063.AUD","BK4568","LU0289739699.SGD","LU1894683264.USD","LU1066053197.SGD","LU0170899867.USD","SG9999013999.USD","LU1169589451.USD","SG9999003800.SGD","688336","LU0306807586.USD","SG9999011175.SGD","SG9999001176.SGD","SG9999002232.USD","IE0002270589.USD","LU0058720904.USD","LU0321505439.SGD","BK0239","LU0122379950.USD","LU0225771236.USD","LU1057294990.SGD","IE00BLSP4239.USD","SG9999001176.USD","LU0321505868.SGD","BK4588","IE00B19Z3B42.SGD","IE00BBT3K403.USD","BK4585","LU0225284248.USD","PFE","IE00B19Z3581.USD","IE000M9KFDE8.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1144514447","title":"Sunshine Guojian Licenses Global Rights of 707 Project to Pfizer","url":"https://stock-news.laohu8.com/highlight/detail?id=1144514447","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144514447?lang=en_us&edition=fundamental","pubTime":"2025-10-31 22:41","pubTimestamp":1761921683,"startTime":"0","endTime":"0","summary":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. announced on October 31 that it has licensed the global rights of its 707 project to Pfizer. The subsequent clinical development will be led by Pfizer, while Sunshine Guojian will continue focusing on the autoimmune disease field.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","SG9999011175.SGD","BK4588","LU0122379950.USD","LU1023059063.AUD","BK4534","BK4585","LU0234572021.USD","IE00BBT3K403.USD","LU1057294990.SGD","PFE","LU0058720904.USD","IE00BLSP4239.USD","LU1066053197.SGD","SG9999002232.USD","LU0321505439.SGD","IE000M9KFDE8.USD","LU0225771236.USD","BK4592","BK0239","SG9999002224.SGD","LU0170899867.USD","BK4550","IE00B19Z3B42.SGD","LU0321505868.SGD","SG9999001176.USD","IE00B19Z3581.USD","LU0868494617.USD","LU1894683348.USD","LU0289739699.SGD","SG9999001176.SGD","688336","BK4599","LU1894683264.USD","LU0225284248.USD","BK4581","IE0002270589.USD","LU0306806265.USD","SG9999013999.USD","SGXZ57979304.SGD","LU1883839398.USD","LU0985481810.HKD","IE00BLSP4452.SGD","BK4007","LU1066051498.USD","SG9999003800.SGD","LU0456855351.SGD","BK4533","LU0306807586.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2577569157","title":"Sunshine Guojian Pharma's Q3 Profit Soars 101%, Revenue Jumps 38%; Shares Dip 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577569157","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577569157?lang=en_us&edition=fundamental","pubTime":"2025-10-24 13:42","pubTimestamp":1761284573,"startTime":"0","endTime":"0","summary":"Sunshine Guojian Pharmaceutical Shanghai's  net profit attributable to shareholders in the third quarter soared 101% year on year to 208.5 million yuan, according to a Shanghai bourse filing on Friday.Earnings per share surged 100% year on year to 0.34 yuan.Operating revenue jumped 38% from a year earlier to almost 474 million yuan.The Chinese pharmaceutical company's shares dropped over 7% in the afternoon trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-07-22","address":"上海市浦东新区中国(上海)自由贸易试验区李冰路399号","stockEarnings":[{"period":"1week","weight":0.2904},{"period":"1month","weight":0.6506},{"period":"3month","weight":0.5494},{"period":"6month","weight":0.6252},{"period":"1year","weight":2.3803},{"period":"ytd","weight":0.5494}],"companyName":"三生国健药业(上海)股份有限公司","boardCode":"AI0027","perCapita":"39004股","boardName":"医药制造业","registeredCapital":"61808万元","compareEarnings":[{"period":"1week","weight":-0.0086},{"period":"1month","weight":-0.0496},{"period":"3month","weight":-0.0224},{"period":"6month","weight":-0.0007},{"period":"1year","weight":0.161},{"period":"ytd","weight":-0.0224}],"survey":"　　三生国健药业(上海)股份有限公司的主营业务是抗体药物的研发、生产和销售。公司的主要产品是益赛普、赛普汀、健尼哌、益赛拓。公司是“免疫与炎症全国重点实验室”依托单位、拥有抗体药物国家工程研究中心、国家企业技术中心、上海市抗体技术创新中心、上海抗体工程技术研究中心等国家级和上海市级高新技术平台，承担过国家重大新药创制、“863”计划、国家发改委及上海市重大项目及各部委课题百余项，多次获得上海市级和浦东新区科学技术奖。","serverTime":1775265278002,"listedPrice":28.18,"stockholders":"15813人(较上一季度增加31.98%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Sunshine Guojian Pharmaceutical(Shanghai)Co.,Ltd.(688336),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Sunshine Guojian Pharmaceutical(Shanghai)Co.,Ltd.(688336) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Sunshine Guojian Pharmaceutical(Shanghai)Co.,Ltd.,688336,Sunshine Guojian Pharmaceutical(Shanghai)Co.,Ltd.股票,Sunshine Guojian Pharmaceutical(Shanghai)Co.,Ltd.股票老虎,Sunshine Guojian Pharmaceutical(Shanghai)Co.,Ltd.股票老虎国际,Sunshine Guojian Pharmaceutical(Shanghai)Co.,Ltd.行情,Sunshine Guojian Pharmaceutical(Shanghai)Co.,Ltd.股票行情,Sunshine Guojian Pharmaceutical(Shanghai)Co.,Ltd.股价,Sunshine Guojian Pharmaceutical(Shanghai)Co.,Ltd.股市,Sunshine Guojian Pharmaceutical(Shanghai)Co.,Ltd.股票价格,Sunshine Guojian Pharmaceutical(Shanghai)Co.,Ltd.股票交易,Sunshine Guojian Pharmaceutical(Shanghai)Co.,Ltd.股票购买,Sunshine Guojian Pharmaceutical(Shanghai)Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Sunshine Guojian Pharmaceutical(Shanghai)Co.,Ltd.(688336),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Sunshine Guojian Pharmaceutical(Shanghai)Co.,Ltd.(688336) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction